Drug class
CFTR corrector; component of elexacaftor/tezacaftor/ivacaftor combination
Mechanism of action
Binds CFTR at a distinct site from tezacaftor and improves folding, processing and trafficking of F508del-mutant CFTR to the cell surface. It is used with tezacaftor and ivacaftor, which further correct CFTR processing and potentiate channel opening.
General use cases
- Component of the fixed triple combination TRIKAFTA/KAFTRIO for treatment of cystic fibrosis in eligible patients with at least one responsive CFTR mutation; not a standalone approved indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
